🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Fostering Data Sharing

Search Papers Authors Institutions Grants FAIR About

TheSindex

Fostering Data Sharing

Empowering the data sharing that empowers science — an open, citation-grounded index for datasets.

Product

Search
API
Explore
Rankings

Resources

Methodology
Data Sources
Documentation
Press

Organization

About
Team
Wikidata

© 2026 theSindex. All rights reserved.

Home
Authors
Rosalba Martignetti

Rosalba Martignetti

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial”.

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial

The Lancet Haematology(2021)10.1016/s2352-3026(21)00307-0

N/A

3.8DataRank · unranked

110 citations

Anthony R Mato, Ahmet Dogan, Venkatraman E Seshan, Erel Joffe, Kelsey Flaherty +41 more

Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0964

N/A

0DataRank · unranked

13 citations

Tatyana Feldman, Jacob D. Soumerai, Victoria Falco, Gail Panton, Colleen Dorsey +21 more

Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

(2023)10.1158/1078-0432.c.6532596

N/A

0DataRank · unranked

0 citations

Tatyana Feldman, Jacob D. Soumerai, Victoria Falco, Gail Panton, Colleen Dorsey +21 more

Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

(2023)10.1158/1078-0432.c.6532596.v1

N/A

0DataRank · unranked

0 citations

Tatyana Feldman, Jacob D. Soumerai, Victoria Falco, Gail Panton, Colleen Dorsey +21 more